Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial.

BACKGROUND Additional benefits of the dual-hormone (insulin and glucagon) artificial pancreas compared with the single-hormone (insulin alone) artificial pancreas have not been assessed in young people in outpatient unrestricted conditions. We evaluated the efficacy of three systems for nocturnal glucose control in children and adolescents with type 1 diabetes. METHODS We did a randomised, three-way, crossover trial in children aged 9-17 years with type 1 diabetes attending a diabetes camp in Canada. With use of sealed envelopes, children were randomly assigned in a 1:1:1:1:1:1 ratio with blocks of six to different sequences of the three interventions (single-hormone artificial pancreas, dual-hormone artificial pancreas, and conventional continuous subcutaneous insulin pump therapy). Each intervention was applied for 3 consecutive nights. Participants, study staff, and endpoint assessors were not masked. The primary outcome was the percentage of time spent with glucose concentrations lower than 4·0 mmol/L from 2300 h to 0700 h. Analysis was by intention to treat. A p value of less than 0·0167 was regarded as significant. This study is registered with ClinicalTrials.gov, number NCT02189694. FINDINGS Between June 30, 2014, and Aug 9, 2014, we enrolled 33 children of mean age 13·3 years (SD 2·3; range 9-17). The time spent at a glucose concentration lower than 4·0 mmol/L was median 0% (IQR 0·0-2·4) during nights with the dual-hormone artificial pancreas, 3·1% (0·0-6·9) during nights with the single-hormone artificial pancreas (p=0·032), and 3·4% (0-11·0) during nights with conventional pump therapy (p=0·0048 compared with dual-hormone artificial pancreas and p=0·32 compared with single-hormone artificial pancreas). 15 hypoglycaemic events (<3·1 mmol/L for 20 min measured by sensor then confirmed with capillary glucose <4·0 mmol/L) were noted during nights with conventional pump therapy compared with four events with the single-hormone system and no events with the dual-hormone system. None of the assessed outcomes varied with the order in which children and young adults were assigned interventions. INTERPRETATION The dual-hormone artificial pancreas could improve nocturnal glucose control in children and adolescents with type 1 diabetes. Longer and larger outpatient studies are now needed. FUNDING Canadian Diabetes Association, Fondation J A De Sève.

[1]  Frances Whinder,et al.  Diabetes management goes digital. , 2013, The lancet. Diabetes & endocrinology.

[2]  P A Cleary,et al.  Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). , 2001, The Journal of pediatrics.

[3]  Roman Hovorka,et al.  Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. , 2014, The lancet. Diabetes & endocrinology.

[4]  Roman Hovorka,et al.  Closed-loop insulin delivery: from bench to clinical practice , 2011, Nature Reviews Endocrinology.

[5]  R. Streisand,et al.  Nighttime caregiving behaviors among parents of young children with Type 1 diabetes: associations with illness characteristics and parent functioning. , 2009, Families, systems & health : the journal of collaborative family healthcare.

[6]  David M Nathan,et al.  Outpatient glycemic control with a bionic pancreas in type 1 diabetes. , 2014, The New England journal of medicine.

[7]  Ahmad Haidar,et al.  Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial , 2013, Canadian Medical Association Journal.

[8]  E. Atlas,et al.  Nocturnal glucose control with an artificial pancreas at a diabetes camp. , 2013, The New England journal of medicine.

[9]  Ahmad Haidar,et al.  Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. , 2015, The lancet. Diabetes & endocrinology.

[10]  T. Jones,et al.  Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. , 2013, JAMA.

[11]  F. Ovalle,et al.  Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes , 2009 .

[12]  Tadej Battelino,et al.  MD-Logic Overnight Control for 6 Weeks of Home Use in Patients With Type 1 Diabetes: Randomized Crossover Trial , 2014, Diabetes Care.

[13]  T. Jones,et al.  Hypoglycemia: Incidence and Clinical Predictors in a Large Population-Based Sample of Children and Adolescents with IDDM , 1997, Diabetes Care.

[14]  David M Maahs,et al.  Epidemiology of type 1 diabetes. , 2010, Endocrinology and metabolism clinics of North America.

[15]  E. Atlas,et al.  Night glucose control with MD‐Logic artificial pancreas in home setting: a single blind, randomized crossover trial—interim analysis , 2014, Pediatric diabetes.

[16]  W. Kenneth Ward,et al.  Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes , 2010, Diabetes Care.

[17]  Marc D. Breton,et al.  Overnight Glucose Control With an Automated, Unified Safety System in Children and Adolescents With Type 1 Diabetes at Diabetes Camp , 2014, Diabetes Care.

[18]  George Dailey,et al.  Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. , 2010, The New England journal of medicine.

[19]  R. Rabasa-Lhoret,et al.  Association between post-dinner dietary intakes and nocturnal hypoglycemic risk in adult patients with type 1 diabetes. , 2014, Diabetes research and clinical practice.

[20]  R. Beck,et al.  Most Youth With Type 1 Diabetes in the T1D Exchange Clinic Registry Do Not Meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes Clinical Guidelines , 2013, Diabetes Care.

[21]  Malgorzata E. Wilinska,et al.  Overnight Closed-Loop Insulin Delivery in Young People With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial , 2014, Diabetes Care.

[22]  H. Mortensen,et al.  Findings from the Hvidøre Study Group on Childhood Diabetes: Metabolic Control and Quality of Life1 , 2004, Hormone Research in Paediatrics.